Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-01
2008-01-01
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
10420445
ABSTRACT:
Compounds having the formula (I),and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are surprisingly advantageous as p38 kinase inhibitors, wherein R3is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, NH2, or NH(CH3), preferably methyl; X is N or CH; and R1through R6are as described in the specification.
REFERENCES:
patent: 6147080 (2000-11-01), Bemis et al.
patent: 6251914 (2001-06-01), Adams et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 2002/0065270 (2002-05-01), Moriarty et al.
patent: 2002/0137747 (2002-09-01), Moriarty et al.
patent: 2003/0069244 (2003-04-01), Leftheris et al.
patent: 2003/0139435 (2003-07-01), Ahmed et al.
patent: 2003/0186982 (2003-10-01), Godfrey, Jr. et al.
patent: 2003/0186983 (2003-10-01), Mastalerz et al.
patent: 2004/0023992 (2004-02-01), Das et al.
patent: 2004/0063707 (2004-04-01), Bhide et al.
patent: 2004/0063708 (2004-04-01), Bhide et al.
patent: 2004/0072832 (2004-04-01), Bhide et al.
patent: 2004/0077858 (2004-04-01), Bhide et al.
patent: 2004/0142931 (2004-07-01), Vite et al.
patent: WO00/20402 (2000-04-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 01/14378 (2001-03-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 03/091229 (2003-11-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, p. 596.
Henry et al., Drugs. Fut., vol. 24, pp. 1345-1354 (1999).
Rankin et al., Br. J. Rheumatol., vol. 34, pp. 334-342 (1995).
Moreland et al., Ann. Intern.Med., vol. 130, pp. 478-486 (1999).
Branger, J., et al., “Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia”, The Journal of Immunology, vol. 168, pp. 4070-4077, (2002).
Davis, J. C., Jr., “Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis”, Seminars in Arthritis and Rheumatism, vol. 34, pp. 668-677, (2004).
Gottlieb, A. B., et al., TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques1, The Journal of Immunology, vol. 175, pp. 2721-2729, (2005).
Hideshima, T. et al, “Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu”, Blood, vol. 101(2), pp. 703-706, (2003).
Johansen, C., et al., “Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 21”, The Journal of Immunology, vol. 176, pp. 1431-1438, (2006).
Johansen, C., et al., “The mitogen-activated protein kinases p38 and KRK1/2 are increased in lesional psoriatic skin”, British Journal of Dermatology, vol. 152, pp. 37-42, (2005).
Kumar, S., et al., “P38 MAP Kinases: Key Signalling Molecules as Therapeutic Targets for Inflammatory Diseases”, vol. 2, pp. 717-726, (2003).
Mease, P. J., et al., “Psoriatic arthritis treatment: biological response modifiers”, Ann. Rheum. Dis., vol. 64 (Suppl. II), pp. ii78-ii82, (2005).
Navas, TA, et al., Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, MCI-1 and p53 levels in vitro and inhibits tumor growth in vivo, Leukemia, 1-11 (2006).
Papp. K. A., “The long-term efficacy and safety of new biological therapies for psoriasis”, Arch. Dermatol. Res. vol. 298, pp. 7-15, (2006).
Saklatvala, J., “The p38 MAP kinase pathway as a therapeutic target in inflammatory disease”, Current Opinion in Pharmacology, vol. 4, pp. 372-377, (2004).
Waetzig G. H., “p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease1”, The Journal of Immunology, vol. 168, pp. 5342-5351, (2002).
Doweyko Arthur M P.
Dyckman Alaric J.
Hynes John
Leftheris Katerina
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Wang Joseph C.
Winslow Anastasia P.
LandOfFree
Aryl ketone pyrrolo-triazine compounds useful as kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl ketone pyrrolo-triazine compounds useful as kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl ketone pyrrolo-triazine compounds useful as kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3938249